REVIEW OF DECISIONS

BOARD MEETING
7-8 December 2016, Abidjan, Côte d’Ivoire
a) appointed the following Board Members:

- **Margaret (Peggy) Hamburg** as an Unaffiliated Board Member in the seat formerly held by HRH Infanta Cristina of Spain effective immediately and until 31 December 2019.

- **Daniel Graymore** of the United Kingdom as Board Member representing the United Kingdom on the donor constituency anchored by the United Kingdom effective immediately and until 31 December 2019.

- **Shanelle Hall** as Board member representing UNICEF in the seat previously held by Geeta Rao Gupta effective immediately and until her successor is appointed.
• **Ummy Ally Mwalimu** of Tanzania representing the developing country constituency in the seat previously held by Seif Seleman Rashid of Tanzania effective immediately and until 31 December 2017.

• **Myint Htwe** of Myanmar as Board Member representing the developing country constituency in the seat previously held by Ramjanam Chaudhary of Nepal effective immediately and until 31 December 2017.

• **Reina Buijs** of the Netherlands as Board Member representing the Netherlands on the donor constituency anchored by Norway effective 1 January 2017 and until 31 December 2018.
DECISION 1: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (3/10)

• Jan Paehler of the European Commission as Board Member representing the European Commission on the donor constituency anchored by Germany effective 1 January 2017 and until 31 December 2017.

• Susan Tolton of Canada as Board Member representing Canada on the donor constituency anchored by Canada effective 1 January 2017 and until 31 December 2018.
b) appointed the following Alternate Board Members:

- **Ted Chaiban** as Alternate Board member to Shanelle Hall representing UNICEF in the seat previously held by Shanelle Hall effective immediately and until his successor is appointed.

- **Yifru Berhan Mitke** of Ethiopia as Alternate Board Member representing the developing country constituency in the seat previously held by Kesetebirhan Admasu of Ethiopia effective immediately and until 31 December 2017.

- **Anna Hamrell** of Sweden as Alternate Board Member to Reina Buijs of the Netherlands representing the donor constituency anchored by Norway effective 1 January 2017 until 31 December 2018.
DECISION 1: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (5/10)

- **Jean-François Pactet** of France as Alternate Board Member to Jan Paehler of the European Commission representing the donor constituency anchored by Germany effective 1 January 2017 until 31 December 2017.

- **Angela Santoni** of Italy as Alternate Board Member to Susan Tolton of Canada, representing the donor constituency anchored by Canada effective 1 January 2017 until 31 December 2017.

- **Lyn Morgan** as Alternate Board Member representing the industrialised vaccine industry constituency in the seat currently held by Laura Laughlin effective 1 January 2017 until 31 July 2017.
c) **reappointed** the following Alternate Board Members:

- **Jason Lane** of the United Kingdom as Alternate Board Member to Daniel Graymore of the United Kingdom, representing the donor constituency anchored by the United Kingdom until 31 December 2019.

d) **appointed** the following to the Executive Committee effective immediately:

- **Shanelle Hall** (Board Member) until 31 December 2017.
- **Jan Paehler** (Board Member) until 31 December 2017.
DECISION 1: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (7/10)

e) appointed the following to the Governance Committee:

- **Daniel Graymore** (Board Member) effective immediately and until 31 December 2017.
- **Reina Buijs** (Board Member) effective 1 January 2017 and until 31 December 2017.
- **Susan Tolton** (Board Member) effective 1 January 2017 and until 31 December 2017.
- **Lyn Morgan** (Alternate Board Member) effective 1 January 2017 and until 31 July 2017.
DECISION 1: CONSENT AGENDA: BOARD & COMMITTEE MEMBER APPOINTMENTS (8/10)

f) appointed the following to the Audit and Finance Committee effective immediately:
   • Ted Chaiban (Alternate Board Member) until 31 December 2017.
   • Chris Taylor (Committee Delegate) until 31 December 2017.

g) appointed the following to the Programme and Policy Committee effective immediately:
   • Ummy Ally Mwalimu (Board Member) in the seat currently held by Seif Seleman Rashid until 31 December 2017.
   • Jean-François Pactet (Alternate Board Member) in the seat currently held by Mariam Diallo until 31 December 2017.
h) **reappointed** the following to the Programme and Policy Committee:
   - **Jason Lane** (Alternate Board Member) until 31 December 2017.
   - **Lene Lothe** (Committee Delegate) until 31 December 2017.

i) **extended the term** and **reappointed** the following as Chair of the Evaluation Advisory Committee:
   - **Rob Moodie** until 31 December 2018.
h) appointed the following to the Evaluation Advisory Committee effective 1 January 2017:

- **Anna Hamrell** (Alternate Board Member) until 31 December 2018.
- **Nina Schwalbe** (Independent Expert) until 31 December 2019.
- **Viroj Tangcharoensathien** (Independent Expert) until 31 December 2019.
- **Wieneke Vullings** (Independent Expert) until 31 December 2019.
DECISION 2: CONSENT AGENDA: IRC NOMINATIONS

The Gavi Alliance Board:

a) **Extended** the terms of the IRC members listed in Annex A, Table 1 of Document 02b for a further three-year term from 1 April 2017 until 31 March 2020;

b) **Ratified** the emergency appointment of seven IRC members by the Chief Executive Officer in concurrence with the Chair of the Programme and Policy Committee (PPC) under Article 5.1.1 of the By-Laws, whose names are listed in Annex A, Table 2 to Doc 02b, for a term effective 14 October 2016 until 31 March 2019;

c) **Appointed** as new IRC members the individuals listed in Annex A, Table 3 to Doc 02b for terms effective immediately until 31 March 2019.
DECISION 3: CONSENT AGENDA: CHANGES TO COMMITTEE CHARTERS

The Gavi Alliance Board:

(a) **approved** the revised and updated Committee Charter for the Audit and Finance Committee attached as Annex A to Doc 02c; and

(b) **approved** the revised and updated Committee Charter for the Investment Committee attached as Annex B to Doc 02c.
DECISION 4: CONSENT AGENDA: BOARD TRAVEL POLICY REVIEW

The Gavi Alliance Board:

Approved amendments to the Board Travel Policy as outlined in Annex A to Doc 02d.
DEcision 5: consent agenda: programme funding policy update

The Gavi Alliance Board:

**Approved** the amended Gavi Alliance Programme Funding Policy attached as Appendix 1 to Doc 02e.
The Gavi Alliance Board:

Programmes

a) **Approved** the recommendations of the June 2016 New Proposals IRC for new country vaccine programmes to commence in 2017 and 2018.

Budgets

b) **Endorsed** a net increase in programme budgets by US$ 68.0 million for the period 2017-2020 to implement the IRC recommendation in (a). This endorsement would constitute acknowledgement of such budget amounts but would not constitute a funding approval, decision, obligation or commitment of the Gavi Alliance or its contributors.
c) Approved an additional amount of US$ 2 million for operational support costs for the Meningitis A bridge funding as approved by the Board in June 2016.
DECISION 7: CONSENT AGENDA: CO-FINANCING WAIVER

The Gavi Alliance Board:

**Found** that exceptional circumstances in South Sudan and Yemen justify the continuation of Gavi support in those countries irrespective of their default status on their 2015 co-financing obligations.
The Gavi Alliance Board:

a) **Approved** certain adjustments to the existing methods of reviewing and approving new Gavi support to facilitate and inform a learning agenda for an updated review and approval process, including:

   i. offering opportunities for review of new Gavi support on a country-by-country basis and outside of the existing IRC schedule;

   ii. enabling IRC members and other impartial technical experts with local/regional expertise to serve in the capacity as independent reviewers as long as there is no conflict of interest;

   iii. leveraging engagement of country stakeholders to provide input and immediately address issues flagged by the reviewers; and
iv. consider, for those countries with relatively smaller Gavi investments, the use of existing review mechanisms such as the HLRP (or the subset of IRC members of the HLRP) to provide funding recommendations on new as well as existing Gavi support.

b) **Noted** the outcome of this process will allow a final design to be presented to the PPC and Board by end 2017.
DECISION 9: 2016 BOARD AND COMMITTEE SELF-EVALUATION

The Gavi Alliance Board:

a) **agreed** with the recommendations of the Governance Committee in relation to the 2016 Board and Committee self-evaluation that seek to elevate Board discussions as presented to the Board in closed session on 6 December 2016; and

b) **noted** the findings relating to committees and **requested** that the Governance Committee analyse these further, bringing options for consideration to the Board retreat in April 2017 with the intention of proposing recommendations to the Board for approval at its June 2017 meeting.
The Gavi Alliance Board:

2016-2017 budget for the Partners Engagement Framework & Secretariat

a) **Agreed** that the budgetary amounts approved by the Board in Decision 12 of the Board Meeting of 2-3 December 2015 for each component of the Gavi Engagement Framework and Budget for Partners and Secretariat for 2016 and separately for 2017, be treated as an overall Budget amount for each component which may be utilised over both years.

b) **Agreed** that capital expenditure of the Secretariat in excess of the capital expenditure budget can be incurred within the overall amount of the Secretariat Engagement Framework and Capital Expenditure budgets for both years.
c) **Agreed** that expenditure on Operational Partnerships, which are a new initiative for which no provision was made in the aforementioned Budget for 2016 and 2017 can be incurred within the overall amount of the Secretariat/Partners’ Engagement Framework budgets for both years.
DECISION 10: FINANCIAL FORECAST AND PROGRAMME FUNDING ENVELOPES (3/5)

The Gavi Alliance Board:

2017 General Programme Funding Envelope for “unrestricted” countries

a) **Approved** a 2017 Programme Funding Envelope for unrestricted countries from which the Secretariat, under the Programme Funding Policy, shall allot funding to programmes until 31 December 2017, to endorse or adjust previously endorsed amounts of programme multi-year budgets for existing programmes and new programmes for an aggregate amount not exceeding US$ 1,306 million.

(These endorsements would constitute acknowledgement of such budget amounts at the time of allotment but would not constitute a funding approval, decision, obligation or commitment of the Gavi Alliance or its contributors.)
Cold Chain Equipment Optimisation Platform Funding Envelope

b) **Approved** a CCEOP Funding Envelope for unrestricted countries from which the Secretariat, under the Programme Funding Policy, shall allot funding to programmes until 31 December 2017, to endorse or adjust previously endorsed amounts of programme multi-year budgets for existing programmes and new CCEOP programmes for an aggregate amount not exceeding US$ 250 million.

(These endorsements would constitute acknowledgement of such budget amounts at the time of allotment but would not constitute a funding approval, decision, obligation or commitment of the Gavi Alliance or its contributors.)
DECISION 10: FINANCIAL FORECAST AND PROGRAMME FUNDING ENVELOPES (5/5)

The Gavi Alliance Board in session without the participation of US citizens and residents:

2017 General Programme Funding Envelope for “restricted” countries

Approved a 2017 Programme Funding Envelope for restricted countries from which the Secretariat, under the Programme Funding Policy, shall allot funding to programmes until 31 December 2017, to Endorse or adjust previously endorsed amounts of programme multi-year budgets for existing programmes and new programmes for an aggregate amount not exceeding US$ 20 million.

(These endorsements would constitute acknowledgement of such budget amounts at the time of allotment but would not constitute a funding approval, decision, obligation or commitment of the Gavi Alliance or its contributors.)
DECISION 11: COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (1/3)

The Gavi Alliance Board:

a) **Noted** that:
   
i. **In June 2015 it**
   
a) **Approved** the creation of an innovative mechanism to strengthen country cold chain systems and advance the Alliance’s Supply Chain Strategy and, ultimately, its coverage and equity goals (the "CCE platform"), the design of which is set out in Section 3 of Doc 15 to the PPC and includes a funding model tiered by country GNI level;
   
b) **Noted** that an amount of US$ 50 million (to be reassessed and potentially increased based on initial applications to the CCE platform) will be allocated from the resources pledged for 2016-2020 (which envisage funding for strategic initiatives to realise Gavi’s new strategy) to launch the implementation of the CCE platform and fund the initial applications in 2016-2017 and **requested** the Secretariat to report back to the PPC and to the Board in 2017 on the implementation of the CCE platform;
ii. At that time, the Secretariat noted that the proposed initial investment of US$ 50 million by Gavi is to launch the platform. The total estimated funding for the platform required for Gavi countries, excluding India, was estimated to be between US$ 240 million and US$ 310 million for five years;

iii. Following the approval of the CCE platform and its subsequent launch, demand for support under the platform has exceeded initial expectations foreseen in the 2015 CCE platform Board decision;

iv. Additional funding is now required for 20 countries that have applied in 2016 for an amount of approximately US$ 150 million; and

v. Additional applications are expected to be received before the first Board meeting in June 2017.
b) **Decided** that:

i. Consistent with the 2015 Board decision, a review of progress and lessons learned of the CCE platform should be presented to the PPC at its meeting in May 2017 and the Board in June 2017, including its links with HSIS, anticipated impact on the market and the quality of the overall immunisation systems, country case studies, an updated demand forecast, and taking into account feedback provided by the IRC on applications reviewed;

ii. Based on that review, the Secretariat will present to the PPC and Board future options for the implementation of the CCEOP; and

iii. In the period up to the Board meeting in June 2017, the total multi-year commitments of grants for CCEOP should not exceed US$ 250 million, requesting the Secretariat to develop strategies for equitable allocation of the funds available.
DECISION 12: FRAGILE SETTINGS, EMERGENCIES AND DISPLACED PERSONS

The Gavi Alliance Board:

Approved the principles for Gavi’s approach to classifying and responding to fragile and emergency settings and situations involving displaced people as embodied in sections 4.5, 5.3, and 6.4 in Doc 08a to the Board, and requested the Secretariat to operationalise these principles into a policy which will replace the 2013 Fragility and Immunisation Policy.
DECISION 13: SYRIA (1/2)

The Gavi Alliance Board:

a) Noted that:

1. WHO has classified Syria as a grade 3 humanitarian emergency for the last three years;
2. for the same period, the World Bank has classified Syria as a Lower-Middle-Income Country and projects it is likely to become IDA-eligible;
3. no GNI per capita estimate has been available for Syria for several years and the last available estimate was US$1,860 in 2007;
4. providing support to immunisation in Syria would require working through partners;
5. Gavi investment in Syria would involve a higher risk tolerance;
b) **Approved**, in order to support immunisation of children in Syria, an annual amount of up to US$ 25 million for 2017 and 2018 for the purpose of procuring Gavi vaccines and cold chain equipment through UNICEF to be allocated from the approved programme funding envelope;

c) **Requested that:**

1. such support shall be aligned with the annual Syria Humanitarian Response Plan;
2. UNICEF, in consultation with WHO and CSO implementing partners, develop a detailed proposal including reporting arrangements and taking into account the principle of equitable access and following the 'whole of Syria'-approach;
3. the PPC and Board be presented with regular updates on implementation
4. this decision be reviewed at the latest at the December 2018 Board meeting to explore further the most efficient ways to support Syrian children.
DECISION 14: RISK MANAGEMENT UPDATE

The Gavi Alliance Board:

**Approved** the Risk & Assurance Report attached as Appendix 1 to Doc 11.
DECISION 15: REVIEW OF GAVI SUPPORT FOR HPV VACCINE

The Gavi Alliance Board:

a) **Approved** that for the HPV vaccine countries can apply:

   i. directly for national introduction, while maintaining the option of implementing a phased national introduction;

   ii. for support for multi-age cohort HPV vaccinations (9-14 years of age) in year one of introduction of the vaccine, including support for 100% of vaccine costs for the additional cohorts, and operational support of up to US$ 0.65 per targeted girl of those cohorts.

b) **Noted** that the additional funding associated with the above approval for the period 2016-2020 is expected to be approximately US$ 72 million.
DECISION 16: GAVI’S SUPPORT FOR EMERGENCY VACCINE STOCKPILES

The Gavi Alliance Board:

a) **Approved** the principles set out in Figure 1 of Doc 13 for Gavi’s support for emergency stockpiles of Gavi-supported vaccines as an integral part of integrated disease control strategies, as amended by discussions at the Board, overriding previous Board decisions on Gavi’s support for emergency stockpiles; and

a) **Noted** that additional funding associated with the adoption of the principles for the period 2017-2020 amount to approximately US$ 86 million for meningitis and cholera.
DECISION 17: GAVI’S CONTINUED ROLE IN YELLOW FEVER CONTROL

The Gavi Alliance Board:

a) Agreed that Gavi’s support for Yellow Fever vaccine be based on the Eliminating Yellow Fever Epidemics Strategy developed by WHO (the “EYE Strategy”).

b) Noted that due to increased supply availability, and the identified need to improve Yellow Fever vaccine coverage in endemic countries, to introduce forecasted expenditure on Yellow Fever vaccine support in Gavi eligible countries in the period 2017-2020 will increase by approximately up to US$ 150 million.
Thank you